Diabetes management (London, England)最新文献_第4页

Phosphatidic acid: a new therapeutic lead to suppress hepatic glucose production. 磷脂酸:一种新的抑制肝糖生成的治疗先导物。

Diabetes management (London, England) Pub Date : 2014-01-01 DOI: 10.2217/dmt.14.29

Anil K Agarwal, Shireesha Sankella

引用次数: 3

Effective interventions to improve medication adherence in Type 2 diabetes: a systematic review. 改善 2 型糖尿病患者服药依从性的有效干预措施：系统综述。

Diabetes management (London, England) Pub Date : 2014-01-01 DOI: 10.2217/dmt.13.62

Joni L Strom Williams, Rebekah J Walker, Brittany L Smalls, Jennifer A Campbell, Leonard E Egede

{"title":"Effective interventions to improve medication adherence in Type 2 diabetes: a systematic review.","authors":"Joni L Strom Williams, Rebekah J Walker, Brittany L Smalls, Jennifer A Campbell, Leonard E Egede","doi":"10.2217/dmt.13.62","DOIUrl":"10.2217/dmt.13.62","url":null,"abstract":"Aim: Medication adherence is associated with improved outcomes in diabetes. Interventions have been established to help improve medication adherence; however, the most effective interventions in patients with Type 2 diabetes remain unclear. The goal of this study was to distinguish whether interventions were effective and identify areas for future research.Methods: Medline was searched for articles published between January 2000 and May 2013, and a reproducible strategy was used. Study eligibility criteria included interventions measuring medication adherence in adults with Type 2 diabetes.Results: Twenty seven studies met the inclusion criteria and 13 showed a statistically significant change in medication adherence.Conclusion: Heterogeneity of the study designs and measures of adherence made it difficult to identify effective interventions that improved medication adherence. Additionally, medication adherence may not be solely responsible for achieving glycemic control. Researchers must emphasize tailored interventions that optimize management and improve outcomes, and examine the need for clear indicators of medication adherence.","PeriodicalId":89355,"journal":{"name":"Diabetes management (London, England)","volume":"4 1","pages":"29-48"},"PeriodicalIF":0.0,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4157681/pdf/nihms617485.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32662140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Current and future management of diabetic retinopathy: a personalized evidence-based approach. 糖尿病视网膜病变的当前和未来管理:个性化循证方法。

Diabetes management (London, England) Pub Date : 2013-11-01 DOI: 10.2217/dmt.13.50

Ryan J Fante, Thomas W Gardner, Jeffrey M Sundstrom

引用次数: 11

Inducing immune tolerance: a focus on Type 1 diabetes mellitus. 诱导免疫耐受:1型糖尿病的焦点。

Diabetes management (London, England) Pub Date : 2013-09-01 DOI: 10.2217/dmt.13.36

Dan Xu, Suchitra Prasad, Stephen D Miller

{"title":"Inducing immune tolerance: a focus on Type 1 diabetes mellitus.","authors":"Dan Xu, Suchitra Prasad, Stephen D Miller","doi":"10.2217/dmt.13.36","DOIUrl":"https://doi.org/10.2217/dmt.13.36","url":null,"abstract":"Tolerogenic strategies that specifically target diabetogenic immune cells in the absence of complications of immunosuppression are the desired treatment for the prevention or even reversal of Type 1 diabetes (T1D). Antigen (Ag)-based therapies must not only suppress disease-initiating diabetogenic T cells that are already activated, but, more importantly, prevent activation of naive auto-Ag-specific T cells that may become autoreactive through epitope spreading as a result of Ag liberation from damaged islet cells. Therefore, identification of auto-Ags relevant to T1D initiation and progression is critical to the design of effective Ag-specific therapies. Animal models of T1D have been successfully employed to identify potential diabetogenic Ags, and have further facilitated translation of Ag-specific tolerance strategies into human clinical trials. In this review, we highlight important advances using animal models in Ag-specific T1D immunotherapies, and the application of the preclinical findings to human subjects. We provide an up-to-date overview of the strengths and weaknesses of various tolerance-inducing strategies, including infusion of soluble Ags/peptides by various routes of delivery, genetic vaccinations, cell- and inert particle-based tolerogenic approaches, and various other strategies that target distinct tolerance-inducing pathways.","PeriodicalId":89355,"journal":{"name":"Diabetes management (London, England)","volume":"3 5","pages":"415-426"},"PeriodicalIF":0.0,"publicationDate":"2013-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/dmt.13.36","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32097132","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 24

Looking forward to transition: perspectives on transition from pediatric to adult diabetes care. 展望转变:从儿科到成人糖尿病护理转变的观点。

Diabetes management (London, England) Pub Date : 2013-07-01 DOI: 10.2217/dmt.13.27

Jennifer K Raymond, Danny C Duke, Lisa Shimomaeda, Michael A Harris

引用次数: 12

Viruses and Type 1 diabetes: a dynamic labile equilibrium. 病毒与 1 型糖尿病：一种动态的易变平衡。

Diabetes management (London, England) Pub Date : 2013-05-01 DOI: 10.2217/dmt.13.17

Darius A Schneider, Matthias G von Herrath

引用次数: 0

Dissecting gene-environment contributions to Type 2 diabetes. 剖析基因环境对2型糖尿病的影响。

Diabetes management (London, England) Pub Date : 2012-09-01 DOI: 10.2217/dmt.12.47

Braxton D Mitchell, Robert L Hanson

引用次数: 0

Personalized medicine in Type 2 diabetes: what does the future hold? 2型糖尿病的个体化治疗:未来会怎样?

Diabetes management (London, England) Pub Date : 2012-05-01 DOI: 10.2217/dmt.12.15

Richard W Grant, Deborah J Wexler

引用次数: 17

Diabetes prevention: global health policy and perspectives from the ground. 糖尿病预防:全球卫生政策和实地视角。

Diabetes management (London, England) Pub Date : 2012-01-01 DOI: 10.2217/dmt.12.34

Michael Bergman, Martin Buysschaert, Peter Eh Schwarz, Ann Albright, Km Venkat Narayan, Derek Yach

{"title":"Diabetes prevention: global health policy and perspectives from the ground.","authors":"Michael Bergman, Martin Buysschaert, Peter Eh Schwarz, Ann Albright, Km Venkat Narayan, Derek Yach","doi":"10.2217/dmt.12.34","DOIUrl":"https://doi.org/10.2217/dmt.12.34","url":null,"abstract":"Type 2 diabetes and other noncommunicable diseases are a growing public health challenge globally. An estimated 285 million people, corresponding to 6.4% of the world's adult population, has diabetes, which is expected to reach 552 million by the International Diabetes Federation in 2030. A much larger segment of the world's population, approximating 79 million individuals in the USA alone, has prediabetes. Globally, a relatively small percentage of those with diabetes or prediabetes are diagnosed with the potential for developing chronic complications. To address this epidemic, governments, in concert with the private sector, need to set policies that promote healthy nutritional and agricultural policies, favor modifications in the environment that encourage greater physical activity and make prevention affordable for all citizens at high risk. The public health sector has the charge of translating evidence-based findings into practical, accessible and cost-effective programs and monitoring the process to continuously improve prevention initiatives. The clinical sector has the formidable challenge of screening and identifying those at high risk and referring them to accredited intervention programs. There is a need to explore additional cost-effective interventions that are customized to meet individual needs that can be offered at the community and clinical levels. Thus, all three sectors, government, public health and clinical, each have a critical role in this process and by working in a partnership, ought to create the necessary synergies essential for making substantial forays in the prevention of Type 2 diabetes.","PeriodicalId":89355,"journal":{"name":"Diabetes management (London, England)","volume":"2 4","pages":"309-321"},"PeriodicalIF":0.0,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/dmt.12.34","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34146280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 55

Addressing diabetes racial and ethnic disparities: lessons learned from quality improvement collaboratives. 解决糖尿病种族和民族差异:从质量改进合作中吸取的经验教训。

Diabetes management (London, England) Pub Date : 2011-11-01 DOI: 10.2217/dmt.11.48

Abigail E Wilkes, Kristine Bordenave, Lisa Vinci, Monica E Peek

引用次数: 0